埃索美拉唑主治什么？

Esomeprazole is approved for the treatment of gastroesophageal reflux disease (GERD) - erosive reflux esophagitis. - Long-term maintenance treatment to prevent recurrence in patients with cured esophagitis.

In 2000, the oral formulation of esomeprazole (Nexium) was first launched in Sweden. In 2001, it was approved by the FDA to be launched in the United States under the trade name Nexium. In 2003, esomeprazole sodium for injection developed by AstraZeneca was first launched in Sweden and was approved for marketing in the United States in 2005.

Esomeprazole magnesium enteric-coated tablets are the S-isomer of omeprazole. They reduce gastric acid secretion through a specific targeting mechanism and are specific inhibitors of proton pumps in parietal cells. The R-isomer and S-isomer of omeprazole have similar pharmacodynamic properties. Esomeprazole is a weak base, which is concentrated in the high-acid environment of parietal cell acid secretion microtubules and converted into an active form, thereby inhibiting the H+/K+-ATPase (proton pump) at this site, inhibiting both basic gastric acid secretion and stimulated gastric acid secretion.

Gastroesophageal Reflux Disease (GERD) - For the treatment of erosive reflux esophagitis, take 40 mg once daily for four weeks. For patients whose esophagitis has not been cured or who have persistent symptoms, it is recommended to take medication for another four weeks. - Long-term maintenance treatment for cured esophagitis patients to prevent recurrence: 20 mg once daily. To control the symptoms of gastroesophageal reflux disease (GERD), patients without esophagitis should take 20 mg once a day. If the symptoms are not controlled after 4 weeks of medication, the patient should undergo further examination. Once the symptoms are eliminated, immediate treatment can be used for subsequent symptom control, that is, 20 mg orally once a day when necessary. Esomeprazole 20mg and 40mg take effect within one hour after oral administration. Repeated administration of 20 mg once a day for 5 consecutive days, and measurement 6-7 hours after taking the drug on the 5th day, the average peak acid secretion caused by pentagastrin stimulation was reduced by 90%.